Nelarabine is a chemotherapy drug that is used to treat patients with T-cell lymphoblastic lymphoma (T-LBL) and T-cell acute lymphoblastic leukemia (T-ALL). It is marketed under the trade name Arranon by SmithKline Beecham Corporation. Nelarabine has the chemical name 2-Amino-9-((2-deoxy-2-fluoro-beta-D-arabinofuranosyl)oxy)-6,9-dihydro-3H-purin-6-one, a molecular formula of C11H12FN5O4, formula weight of 297.24 g/mol and CAS No. 121032-29-9.
Top 10 Keywords related to Nelarabine from Google are:
Synonyms of Nelarabine are: Arranon, 506U78
Health Benefits of Nelarabine: Nelarabine is a purine nucleoside analog that works by interfering with DNA synthesis and inducing apoptosis, or programmed cell death, in cancer cells. It is used to treat T-cell lymphoblastic lymphoma (T-LBL) and T-cell acute lymphoblastic leukemia (T-ALL), two types of aggressive blood cancers that affect the immune system. Nelarabine is indicated for patients who have not responded to or have relapsed after previous therapy.
Potential Effects of Nelarabine: Nelarabine is a potent chemotherapy agent that has been found to be effective in the treatment of T-LBL and T-ALL. It has been shown to produce high response rates in heavily pretreated patients, with complete responses ranging from 24% to 32%. Nelarabine has also been investigated for use in other types of leukemia and lymphoma, including Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Product Mechanism of Action: Nelarabine is a purine nucleoside analog that is activated to the triphosphate form within cells. It interferes with DNA synthesis by incorporating into DNA and RNA chains, leading to chain termination and inhibition of cell growth and division. Nelarabine also induces apoptosis, or programmed cell death, in cancer cells by activating the caspase cascade.
Safety: Nelarabine is generally safe and well-tolerated in patients with T-LBL and T-ALL. The most common adverse reactions reported with the use of nelarabine include fever, nausea, vomiting, diarrhea, fatigue, and headache. More serious adverse reactions include myelosuppression, infections, neuropathy, and hepatotoxicity.
Side Effects: The side effects of nelarabine depend on the dose and duration of treatment. Common side effects include fever, nausea, vomiting, diarrhea, fatigue, and headache. More serious adverse reactions include myelosuppression, infections, neuropathy, and hepatotoxicity. Patients receiving nelarabine should be closely monitored for signs of infection, bleeding, or hepatotoxicity.
Dosing Information: The recommended dose of nelarabine for the treatment of T-LBL and T-ALL is 650 mg/m2/day for five consecutive days. The dose may be repeated every 21 to 28 days depending on the response and toxicity. The dose and duration of treatment may vary depending on the patient's age, weight, and overall health.
Conclusion: Nelarabine is a potent chemotherapy agent that is used to treat T-cell lymphoblastic lymphoma (T-LBL) and T-cell acute lymphoblastic leukemia (T-ALL), two types of aggressive blood cancers that affect the immune system. It interferes with DNA synthesis and induces apoptosis in cancer cells. Nelarabine is generally safe and well-tolerated in patients with T-LBL and T-ALL, but serious adverse reactions may occur. The recommended dose and duration of treatment may vary depending on the patient's age, weight, and overall health. Patients receiving nelarabine should be closely monitored for signs of infection, bleeding, or hepatotoxicity
